Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer

Cancer Investigation

Volumn 31, Issue 4, 2013, Pages 258-272

  Podzielinski, Iwona ^a   Saunders, Brook A ^b   Kimbler, Kimberly D ^c   Branscum, Adam J ^d   Fung, Eric T ^e   Depriest, Paul D ^f   Van Nagell, John R ^f   Ueland, Frederick R ^f   Baron, Andre T ^f,g  

^a Fort Wayne Medical Oncology   (United States)

^b Knoxville Neurology Specialists   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e Vermillion Inc   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

Author keywords

Cancer biomarkers; Detection diagnosis; Ovarian cancer; Protein profiling; Tumor biology

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYST FLUID; ENDOMETRIOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; CYST FLUID; FEMALE; HUMANS; LIPOPROTEINS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN CYSTS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876910218     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.789896     Document Type: Article

References (133)

1. Kurman RJ, Shih Ie M.The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
2. Jemal A, Bray F, CenterMM, Ferlay J,WardE, FormanD.Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
4. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-2075.
5. Menon U. Ovarian cancer screening. CMAJ 2004; 171:323-324. (Pubitemid 39127980)
6. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73-79.
7. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-1639. (Pubitemid 41540458)
8. Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 2006;10:77-81.
9. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16(Suppl 1):54-59.
10. FDA. FDA clears a test for ovarian cancer: test can help identify potential malignancies, guide surgical decisions 2009 [cited November 2009]; [FDA news release]. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm 182057.htm
11. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clinical Chemistry 2010;56:327-329.
12. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw 2008;6:795-802.
13. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM,Miller D, Santos J, Swenerton K, Gilks CB,Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
14. Knudsen UB, Tabor A,Mosgaard B, Andersen ES, Kjer JJ, Hahn-Pedersen S, Toftager-Larsen K, Mogensen O. Management of ovarian cysts. Acta Obstet Gynecol Scand 2004;83:1012-1021. (Pubitemid 39457477)
15. Oyelese Y, Kueck AS, Barter JF, Zalud I. Asymptomatic postmenopausal simple ovarian cyst. Obstet Gynecol Surv 2002;57:803-809. (Pubitemid 36869649)
16. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-288. (Pubitemid 32458162)
17. Ghahremani M, Foghi A, Dorrington JH. Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999;52: 23-26. (Pubitemid 29118940)
18. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS ONE 2010;5: e10358.
19. Artini PG, Cristello F,Monti M, Cela V, Battaglia C,DAmbrogio G, Genazzani AR. Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecol Endocrinol 2005;21:50-56. (Pubitemid 41097796)
20. Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, Boonstra H, Sweep CG. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001;91:371-377. (Pubitemid 32099239)
21. Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest 2002;54:132-136. (Pubitemid 36184420)
22. Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S, Uzun H, Sanioglu C, Aydinli K, Kosebay D. Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet 2003;83:53-58. (Pubitemid 37162830)
23. Fasciani A, DAmbrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001;75:1218-1221. (Pubitemid 32522624)
24. Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wojcik E, Van Dalen A,Einarsson R. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions frompatients with ovarian carcinoma. Anticancer Res 2004;24:1149-1157. (Pubitemid 38624955)
25. Hazelton D,Nicosia RF,Nicosia SV.Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999;5:823-829.
26. Bischof A, BrieseV, RichterDU, BergemannC, FrieseK, Jeschke U.Measurement of glycodelinAin fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer. Anticancer Res 2005;25:1639-1644. (Pubitemid 40896776)
27. Cherchi PL, Capobianco G, Ambrosini G, Fadda GM, Piga MD, Ruiu G, Fattorini F, Dessole S. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology. Eur J Gynaecol Oncol 2002;23:163-165. (Pubitemid 34297124)
28. de Bruijn HW, ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders JG. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. Tumour Biol 1993;14:105-115. (Pubitemid 23255790)
29. Harlozinska A, Sedlaczek P, Van Dalen A, Rozdolski K, Einarsson R. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 1997;17:4473-4478. (Pubitemid 28081730)
30. Lloyd KO, Yin BW, Tempst P, Erdjument-Bromage H. MUC-6 mucin is a major component of "blood group substance" from human ovarian cyst fluid. Biochim Biophys Acta 2000;1474:410-414. (Pubitemid 30209883)
31. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 2002;95:1886-1893. (Pubitemid 35222168)
32. Swierzko AS, Florczak K, Cedzynski M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sulowska Z. Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother 2007;56:959-971. (Pubitemid 46675295)
33. TavaresMurta BM,Cunha Fde Q,Miranda R,Adad SJ,Murta EF. Differential tumor microenvironment in human ovarian cystic tumors. Tumori 2004;90:491-497. (Pubitemid 39556799)
34. Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 2003;13:771-775. (Pubitemid 38235221)
35. Chudecka-Glaz A, Rzepka-Gorska I. Activin A levels in serum and cyst fluid in epithelial tumors of the ovary. Int J Gynaecol Obstet 2005;89:160-162. (Pubitemid 40585624)
36. Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Inhibin A levels in cyst fluid from epithelial ovarian tumors. Acta Obstet Gynecol Scand 2004;83:501-503. (Pubitemid 38534773)
37. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factoralpha in women with endometriomas and benign andmalignant cystic ovarian tumours. Hum Reprod 2003;18:1681-1685. (Pubitemid 36958050)
38. Ivarsson K, Runesson E, Sundfeldt K,HaegerM, Hedin L, Janson PO, Brannstrom M. The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer Gynecol Oncol 1998;71:420-423. (Pubitemid 29022330)
39. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J,Menczer J, Karasik A. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996;73:1069-1073. (Pubitemid 26131226)
40. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271-276. (Pubitemid 24061738)
41. Punnonen J, Heinonen PK, Kuoppala T, Jansen CT, Punnonen R. Production of interleukin-1 beta and tumour necrosis factoralpha in patients with benign or malignant ovarian tumours. J Cancer Res Clin Oncol 1991;117:587-592.
42. Reis FM, Di Blasio AM, Florio P, Ambrosini G, Di Loreto C, Petraglia F. Evidence for local production of inhibin A and activin A in patients with ovarian endometriosis. Fertil Steril 2001;75:367-373. (Pubitemid 32112116)
43. Santala M, Burger H, Ruokonen A, Stenback F, Kauppila A. Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. Gynecol Oncol 1998;71:465-468. (Pubitemid 29022340)
44. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, Illmensee K. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003;63: 7507-7514. (Pubitemid 37413495)
45. Beratis NG, Kaperonis A, Eliopoulou MI, Kourounis G, Tzingounis VA. Increased activity of lysosomal enzymes in the peritoneal fluid of patients with gynecologic cancers and pelvic inflammatory disease. J Cancer Res Clin Oncol 2005;131:371-376. (Pubitemid 40674622)
46. Boss EA, Peters WH, Roelofs HM, Boonstra H, Steegers EA, Massuger LF. Glutathione S-transferases P1-1 and A1-1 in ovarian cyst fluids. Eur J Gynaecol Oncol 2001;22:427-432. (Pubitemid 34160728)
47. Haeger M, Swahn M, Hahlin M, Horvath G, Bengtsson A. Increased concentrations of neopterin in plasma, ascites and ovarian cyst fluid in malignant tumours compared with benign ovarian tumours. Anticancer Res 1996;16:3189-3192. (Pubitemid 26390272)
48. Koivunen E, Itkonen O, Halila H, Stenman UH. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 1990;50:2375-2378. (Pubitemid 20134498)
49. Kolwijck E, Wevers RA, Engelke UF, Woudenberg J, Bulten J, Blom HJ, Massuger LFAG. Ovarian cyst fluid of serous ovarian tumors contains large quantities of the brain amino acid Nacetylaspartate. PLoS ONE 2010;5:e10293.
50. StenmanM, Paju A,Hanemaaijer R, Tervahartiala T, Leminen A, Stenman UH, Konttinen YT, Sorsa T. Collagenases (MMP-1,-8 and-13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. Tumour Biol 2003;24:9-12. (Pubitemid 36578813)
51. Boss EA, Massuger LF, Thomas CM, Geurts-Moespot A, van Schaik JH, Boonstra H, SweepCG. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res 2002;22:275-282. (Pubitemid 34475312)
52. Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved formis present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998;58:3294-3298. (Pubitemid 28371068)
53. Santala M, Risteli J, Risteli L, Puistola U, Kacinski BM, Stanley ER, Kauppila A. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br J Cancer 1998;77:1825-1831. (Pubitemid 28254618)
54. Zhu GG, Melkko J, Risteli J, Kauppila A, Risteli L. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign andmalignant ovarian tumours. Clin Chim Acta 1994;229:87-97. (Pubitemid 24269175)
55. Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res 1993;53:5028-5032. (Pubitemid 23326204)
56. Furuya M, Ishikura H, Kawarada Y, Ogawa Y, Sakuragi N, Fujimoto S, Yoshiki T. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol 2000;78:106-112. (Pubitemid 30650339)
57. Furuya M, Ishikura H, Ogawa Y, Kawarada Y, Shibata M, Fujimoto S, Yoshiki T. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors. Pathobiology 2000;68:239-244. (Pubitemid 32757299)
58. Darai E, Bringuier AF, Walker-Combrouze F, Feldmann G, Madelenat P, Scoazec JY. Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary. Hum Reprod 1998;13:2831-2835. (Pubitemid 28482737)
59. SundfeldtK, IvarssonK, RaskK,HaegerM,HedinL,Brannstrom M. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res 2001;21:65-70. (Pubitemid 32267626)
60. Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 2004;270:151-156. (Pubitemid 40394484)
61. Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I, SchneiderD. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2003;110:207-210. (Pubitemid 37101320)
62. Kramer S, Leeker M, Jager W. Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy Int J Biol Markers 1998;13:165-168.
63. Rzepka-Gorska I, Chudecka-Glaz A, Kosmowska B. FSHand LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer 2004;11:315-321. (Pubitemid 38832832)
64. van Nagell JR, Jr., Pletsch QA, Goldenberg DM. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms. Cancer Res 1975;35:1433-1437.
65. Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol 2005;26:379-384.
66. Kristjansdottir B, Partheen K, Fung ET,Marcickiewicz J, Yip C, Brannstrom M, Sundfeldt K. Ovarian cyst fluid is a rich proteome resource for detection of newtumor biomarkers. Clin Proteomics 2012;9:14.
67. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
68. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B (Methodological) 1995;57:289-300.
69. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol (Clifton, NJ) 2003;224:149-157.
70. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, Diaz JI, Semmes OJ. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-1085. (Pubitemid 40175756)
71. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006;27: 251-259.
72. Heike Y, Hosokawa M, Osumi S, Fujii D, Aogi K, Takigawa N, Ida M, Tajiri H, Eguchi K, Shiwa M, Wakatabe R, Arikuni H, Takaue Y, Takashima S. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 2005;25:1197-1203. (Pubitemid 40546790)
73. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survivalmodels.AnnOncol 2010;21:1472-1481.
74. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol 2004;15:247-253. (Pubitemid 38716556)
75. Bultel-Brienne S, Lestavel S, Pilon A, Laffont I, Tailleux A, Fruchart JC, Siest G, Clavey V. Lipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins. J Biol Chem 2002;277:36092-36099.
76. Fernandis AZ, Wenk MR. Lipid-based biomarkers for cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:2830-2835.
77. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008;1785:182-206.
78. Peng Y, Akmentin W, Connelly MA, Lund-Katz S, Phillips MC, Williams DL. Scavenger receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasmamembrane domain is a way station for cholesterol trafficking between cells and highdensity lipoprotein. Mol Biol Cell 2004;15:384-396. (Pubitemid 38044971)
79. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics 2011;8:263-277.
80. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011;48:498-515.
81. Mahley RW.Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
82. Lund-Katz S, Liu L, Thuahnai ST, Phillips MC. High density lipoprotein structure. Front Biosci 2003;8:d1044-1054.
83. Olivecrona T, Bengtsson-Olivecrona G, Hultin M, Peterson J, Vilaro S, Deckelbaum RJ, Carpentier YA, Patsch J. What factors regulate the action of lipoprotein lipase Adv Exp Med Biol 1991;285:335-339.
84. Zambon A,Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959-1964. (Pubitemid 29183891)
85. Applebaum-Bowden D. Lipases and lecithin: cholesterol acyltransferase in the control of lipoproteinmetabolism. Curr Opin Lipidol 1995;6:130-135.
86. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009;16:163-171.
87. Hesler CB, Swenson TL, Tall AR. Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem 1987;262:2275-2282. (Pubitemid 17102658)
88. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47. (Pubitemid 16037973)
89. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010;30:156-163.
90. Sundaram M, Yao Z. Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion. Arterioscler Thromb Vasc Biol 2012;32:1073-1078.
91. Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol 2003;83:47-68. (Pubitemid 36572978)
92. Saito H, Lund-Katz S, Phillips MC. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res 2004;43: 350-380. (Pubitemid 38952619)
93. Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003;6:177-187. (Pubitemid 40674521)
94. Sacks FM. The apolipoprotein story. Atheroscler Suppl 2006;7:23-27. (Pubitemid 44093384)
95. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002;164:1-13. (Pubitemid 34765632)
96. Lahiry P, Cao H, Ban MR, Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Huff MW, Connelly PW, Hegele RA. APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. J Lipid Res 2010;51:843-848.
97. Andreassi MG. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. Mutat Res 2009;667:35-43.
98. Verges B.Abnormal hepatic apolipoprotein Bmetabolismin type 2 diabetes. Atherosclerosis 2010;211:353-360.
99. Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res 2008;2008:134059.
100. Pedersen TR. Lipid-lowering drugs and risk for cancer. Curr Atheroscler Rep 2009;11:350-357.
101. Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol 2010;17:6-11.
102. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics Clinical Chemistry 2003;49:1272-1275. (Pubitemid 36900611)
103. KimG,Minig L,Kohn EC. Proteomic profiling in ovarian cancer. Int J Gynecol Cancer 2009;19(Suppl 2):S2-S6.
104. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-12348. (Pubitemid 37271562)
105. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF III., Liotta LA. Biomarker amplification by serumcarrier protein binding. Dis Markers 2003;19:1-10. (Pubitemid 38125650)
106. Petricoin E, III., Liotta LA. Counterpoint: The vision for a new diagnostic paradigm. Clinical Chemistry 2003;49:1276-1278.
107. Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B,Wang YY,Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW.Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890. (Pubitemid 39095590)
108. Ades A, Carvalho JP,Graziani SR, Amancio RF, Souen JS, Pinotti JA,Maranhao RC. Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecologic Oncology 2001;82:84-87. (Pubitemid 32634958)
109. Avall-Lundqvist EH, Peterson CO. Serum cholesterol and apolipoprotein B levels may reflect disease activity in ovarian cancer patients. Acta Oncol 1996;35:1007-1010. (Pubitemid 27076973)
110. Gadomska H, Grzechocinska B, Janecki J, Nowicka G, Powolny M, Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 2005;120:87-90. (Pubitemid 40615078)
111. Gadomska H, Janecki J, Marianowski L, Nowicka G. Lipids in serum of patients with malignant ovarian neoplasms. Int J Gynaecol Obstet: the official organ of the International Federation of Gynaecology and Obstetrics 1997;57:287-293. (Pubitemid 27252566)
112. Maranhao RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 1993;28:691-696. (Pubitemid 23241433)
113. Maranhao RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, Meneghetti JC, Pileggi FJ, Chamone DA. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 1994;54:4660-4666.
114. Maranhao RC, Garicochea B, Silva EL, Llacer PD, Pileggi FJ, Chamone DA. Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz J Med Biol Res 1992;25:1003-1007.
115. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acutemyelogenous leukemia cells. Blood 1978;52:1099-1114. (Pubitemid 9071618)
116. Peterson C, Vitols S, Rudling M, Blomgren H, Edsmyr F, Skoog L. Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med Oncol Tumor Pharmacother 1985;2:143-147. (Pubitemid 16245667)
117. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2872-2881.
118. Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih Ie M. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005;65:331-337. (Pubitemid 40070826)
119. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P. Afamin and apolipoprotein AIV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127-1133.
120. Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res 2008;7:3776-3788.
121. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-694. (Pubitemid 40255487)
122. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI. Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry 2006;71:354-360.
123. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ,Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-6287.
124. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-4596. (Pubitemid 41739936)
125. Kuesel AC, Kroft T, Prefontaine M, Smith IC. Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer 1992;52:341-346.
126. Moore LE, Fung ET,McGuire M, Rabkin CC,Molinaro A,Wang Z, Zhang F, Wang J, Yip C, Meng XY, Pfeiffer RM. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006;15:1641-1646. (Pubitemid 44497099)
127. Vazquez J, Gonzalez L,Merino A, Vizoso F. Expression and clinical significance of apolipoprotein D in epithelial ovarian carcinomas. Gynecol Oncol 2000;76:340-347. (Pubitemid 30131505)
128. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T,Modugno F,Marks J, Godwin A, Gorelik E, Jacobs I,Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-2166.
129. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-3876. (Pubitemid 32720943)
130. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R.The early detection of ovarian cancer: from traditional methods to proteomics.Can we really do better than serumCA-125 Am J Obstet Gynecol 2008;199:215-223.
131. Wang Z, Yip C, Ying Y,Wang J,Meng XY, Lomas L, Yip TT, Fung ET. Mass spectrometric analysis of protein markers for ovarian cancer. Clin Chem 2004;50:1939-1942.
132. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu LH, Bast RC Jr. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011;122:548-553.
133. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. JNCI Cancer Spectr 2001;93:1054-1061. (Pubitemid 32717537)